Long‐term effects of rasagiline and the natural history of treated Parkinson's disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Movement Disorders

• Publication date

  2016-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.26724PMID 27431201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

  2015cited by this paper
• Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD

  2013cited by this paper
• The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

  2013cited by this paper
• Progression of motor symptoms in Parkinson’s disease

  2012cited by this paper
• Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

  2012cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

  2011cited by this paper
• The natural history of treated Parkinson's disease in an incident, community based cohort

  2011cited by this paper
• CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

  2010cited by this paper
• A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

  2009cited by this paper
• Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

  2009cited by this paper
• The clinical progression of Parkinson's disease.

  2009cited by this paper
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

  2008cited by this paper
• What's new? Clinical progression and staging of Parkinson's disease.

  2006cited by this paper
• Selegiline slows the progression of the symptoms of Parkinson disease

  2006cited by this paper
• Progression of motor impairment and disability in Parkinson disease

  2005cited by this paper
• The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

  2002cited by this paper
• Selegiline delays the onset of disability in de novo parkinsonian patients

  1998cited by this paper

• Sources of Oxidative Stress in Parkinson's Disease: Pathways and Therapeutic Implications.

  2026cites this paper
• Pharmacotherapy in Early Parkinson’s Disease: A Pragmatic Approach

  2025cites this paper
• Neuroprotection in Parkinson Disease

  2025cites this paper
• Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease.

  2023cites this paper
• Isradipine, an L-type calcium channel inhibitor, attenuates cue-associated methamphetamine-seeking in mice.

  2023cites this paper
• Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

  2023cites this paper
• Interventions for preventing falls in Parkinson's disease.

  2022cites this paper
• A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease

  2022cites this paper
• Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and neurodegeneration with brain iron accumulation disorders.

  2022cites this paper
• Diagnosis and Medical Management of Parkinson Disease

  2022cites this paper
• Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies

  2022cites this paper
• Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases

  2022cites this paper
• The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes

  2022cites this paper
• Prevalence of freezing of gait in Parkinson’s disease: a systematic review and meta-analysis

  2021cites this paper
• German Guidelines for the Use of Parkinsonian Drugs

  2021cites this paper
• Seeking progress in disease modification in Parkinson disease.

  2021cites this paper
• Advancing Personalized Medicine in Common Forms of Parkinson’s Disease through Genetics: Current Therapeutics and the Future of Individualized Management

  2021cites this paper
• Guidelines for the Use of Parkinsonian Drugs (in USA)

  2020cites this paper
• Guidelines for the Use of Parkinsonian Drugs in Canada

  2020cites this paper
• Parkinsonian Drugs: Indications

  2020cites this paper
• Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update

  2020cites this paper
• Parkinson's disease therapy with Istradefylline and blood biomarkers of epigenetics

  2020cites this paper
• Ferroptosis and its potential role in the physiopathology of Parkinson's Disease.

  2020cites this paper
• Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson’s Disease

  2020cites this paper
• Progress of Pharmacological Approaches in Parkinson's Disease

  2019cites this paper
• Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease

  2019cites this paper
• Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities

  2019cites this paper
• Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes

  2019cites this paper
• Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia

  2019cites this paper
• An inducible MAO-B mouse model of Parkinson’s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics

  2018cites this paper
• Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects

  2018cites this paper
• International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

  2018cites this paper
• Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

  2018cites this paper
• Real world studies are essential for drug therapy in Parkinson’s disease

  2018cites this paper
• Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel

  2018cites this paper
• Long term follow-up study of non-invasive brain stimulation (NBS) (rTMS and tDCS) in Parkinson's disease (PD). Strong age-dependency in the effect of NBS.

  2018cites this paper
• Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson

  2017cites this paper
• Treatment Strategies in Early Parkinson's Disease.

  2017cites this paper
• Neue Therapien am Horizont?

  2017cites this paper
• [Pharmacological treatment of motor symptoms in Parkinson's diseases].

  2017cites this paper
• Krankheitsmodifizierender Effekt nicht bestätigt

  2017cites this paper
• Evolução da doença de Parkinson - operacionalização da decisão cirúrgica

  2017cites this paper
• Clinical approaches to the development of a neuroprotective therapy for PD

  2017cites this paper
• Algorithms for the treatment of motor problems in Parkinson's disease

  2017cites this paper